Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Common Equity (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Common Equity data on record, last reported at $245.8 million in Q3 2025.

  • For Q3 2025, Common Equity rose 19.65% year-over-year to $245.8 million; the TTM value through Sep 2025 reached $245.8 million, up 19.65%, while the annual FY2024 figure was $222.9 million, 24.37% up from the prior year.
  • Common Equity reached $245.8 million in Q3 2025 per GLUE's latest filing, down from $268.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $275.2 million in Q1 2025 and bottomed at $152.5 million in Q1 2024.
  • Average Common Equity over 3 years is $219.6 million, with a median of $222.9 million recorded in 2024.
  • Peak YoY movement for Common Equity: plummeted 37.42% in 2024, then surged 80.41% in 2025.
  • A 3-year view of Common Equity shows it stood at $179.2 million in 2023, then grew by 24.37% to $222.9 million in 2024, then grew by 10.27% to $245.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $245.8 million in Q3 2025, $268.1 million in Q2 2025, and $275.2 million in Q1 2025.